Guide to taking budesonide extended-release capsules correctly

Budesonide extended-release capsules, as a highly potent corticosteroid drug, are designed for patients 8 years of age and older with mild to moderately active Crohn's disease (affecting the ileum and/or ascending colon), and can effectively help adult patients maintain clinical remission for up to 3 months. Budesonide exhibits unique advantages in the treatment of Crohn's disease due to its excellent anti-inflammatory glucocorticoid effect and low mineralocorticoid activity.

1. How to take

Patients should take budesonide extended-release capsules once daily in the morning and swallow them whole without chewing or crushing. For patients who have difficulty swallowing the entire capsule, the following special way of taking it can be adopted: open the capsule, pour the granules into a tablespoon of applesauce, mix well, and then finish taking the capsule within 30 minutes. However, the granules should not be chewed or crushed. You should drink 8 ounces (approximately 227 ml) of water immediately after taking it. During treatment, you should avoid drinking grapefruit juice to prevent it from affecting the effectiveness of the medicine.

2. Dosage guidance

1. Treatment of Mild to Moderate Crohn’s Disease:

1) Adult patients with mild to moderately active Crohn's disease: It is recommended to take 9 mg once a day for 8 weeks. If the condition relapses, another 8-week course of treatment can be performed.

2) Pediatric patients aged 8 to 17 years old and weighing more than 25 kg: initially take 9 mg once a day for 8 weeks; then adjust to 6 mg once a day in the morning for another 2 weeks.

2. Adult patients who need to maintain clinical remission:

1) Once a day, 6 mg each time for 3 months; gradually reduce to complete stop after 3 months. It should be noted that long-term treatment (more than 3 months) does not show additional clinical benefit, so the treatment plan should be adjusted appropriately according to the condition.

2) When switching from oral prednisolone to budesonide sustained-release capsules, the dosage of prednisolone should be gradually reduced and budesonide treatment should be started at the same time.

3. Medication for Special Populations

1. Adult patients with moderate hepatic impairment (Child-Pugh class B): It is recommended to reduce the dose to 3 mg once daily.

2. Patients with severe hepatic impairment (Child-Pugh class C): should avoid using budesonide extended-release capsules.

In summary, budesonide extended-release capsules provide an effective treatment option for patients with Crohn's disease. However, in order to ensure the safety and effectiveness of the treatment, patients must strictly follow the doctor's instructions and accurately grasp the taking method and dosage. During the treatment process, you should pay close attention to your body's reaction. If you encounter any discomfort or questions, you should seek medical treatment and consult a professional doctor in time.

Reference materials:https://www.drugs.com/pro/entocort-ec.html#s-34090-1